research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
Search
for
Sort by
Research
90-120 / 1000+ results research Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata
Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.
research Evaluation of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata: A randomized observer-blinded, placebo-controlled, split-head pilot study
Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.
research Comparative study of efficacy of topical mometasone with calcipotriol versus mometasone alone in the treatment of alopecia areata
Combining calcipotriol with mometasone is more effective for treating alopecia areata than using mometasone alone.
research Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
research Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata
Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
research The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial
Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.
research A clinical study on alopecia areata
Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
research Development of the AAcQLI : A New Instrument for Assessing Quality of Life in Children With Alopecia Areata
The AAcQLI is a promising tool for assessing quality of life in children with alopecia areata.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Dermoscopic Analysis of Patients with and without Poor Prognostic Indicators in Alopecia Areata – A Comparative Study
Certain hair and scalp features indicate a worse outcome in alopecia areata.
research COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
Baricitinib works better than methotrexate for severe alopecia areata.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Comparative Evaluation of Efficacy Between Topical Calcipotriol Used Along With Topical Clobetasol And Topical Clobetasol Monotherapy In Treatment Of Alopecia Areata: A Randomised Clinical Trial
Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
research Tratamento adjuvante com minoxidil oral para tratamento de alopecia areata refratária a inibidores de JAK
Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
research Response to “Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis” and an investigation of vitamin D in pediatric patients
Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.
research Safety and efficacy of microneedling with autologous platelet-rich plasma in chronic and stable alopecia areata
Microneedling with PRP is a safe and effective way to treat chronic alopecia areata, improving hair regrowth with minimal side effects.
research Rapid Hair Regrowth in Localized Alopecia Areata Following Low-Dose Intralesional Corticosteroid
Low-dose intralesional corticosteroid treatment led to rapid hair regrowth in localized alopecia areata.
research Advancing Hair Loss Assessment in Alopecia Areata: The Mathematical Case for Centralised, Standardised Imaging
Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research SALT Score Cards: Facilitating SALT Score Calculation in Alopecia Areata
A new tool simplifies alopecia areata severity scoring but needs validation.